INFUSE® (senofilcon A) Multifocal
Presbyopia Correction
LaunchedCommercial
Key Facts
About Bausch + Lomb
Bausch + Lomb is a leading, pure-play eye health company with a mission to protect and enhance sight globally. Its strategic separation from Bausch Health in 2022 unlocked its potential to focus on the high-growth dynamics of the vision care market. The company's strength lies in its integrated portfolio across Vision Care, Pharmaceuticals, and Surgical segments, supported by significant R&D in material science and drug delivery. Its strategy is centered on innovation, geographic expansion, and leveraging its trusted brand to capitalize on powerful demographic tailwinds.
View full company profileTherapeutic Areas
Other Presbyopia Correction Drugs
| Drug | Company | Phase |
|---|---|---|
| Multifocal/EDOF IOLs (in development) | Hoya Surgical Optics | Pre‑clinical |